The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04801420
Recruitment Status : Active, not recruiting
First Posted : March 17, 2021
Results First Posted : June 7, 2023
Last Update Posted : April 10, 2024
Sponsor:
Collaborator:
Valneva Austria GmbH
Information provided by (Responsible Party):
Pfizer

Tracking Information
First Submitted Date  ICMJE March 8, 2021
First Posted Date  ICMJE March 17, 2021
Results First Submitted Date  ICMJE March 24, 2023
Results First Posted Date  ICMJE June 7, 2023
Last Update Posted Date April 10, 2024
Actual Study Start Date  ICMJE March 8, 2021
Actual Primary Completion Date March 25, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 10, 2023)
  • Percentage of Participants With Solicited Local and Solicited Systemic Adverse Events (AEs) Within 7 Days After Vaccination 1 [ Time Frame: From Day 1 to Day 7 after vaccination 1 at Month 0 ]
    Participants or their legal guardians were required to record any solicited local and systemic adverse events in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema (redness), swelling and induration (hardening). Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever. Two-sided 95% confidence intervals were calculated according to Altman method.
  • Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 2 [ Time Frame: From Day 1 to Day 7 after vaccination 2 at Month 2 ]
    Participants or their legal guardians were required to record any solicited local and systemic adverse events in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema (redness), swelling and induration (hardening). Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever. Two-sided 95% confidence intervals were calculated according to Altman method.
  • Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 3 [ Time Frame: From Day 1 to Day 7 after vaccination 3 at Month 6 ]
    Participants or their legal guardians were required to record any solicited local and systemic adverse events in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema (redness), swelling and induration (hardening). Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever. Two-sided 95% confidence intervals were calculated according to Altman method.
  • Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Any Vaccination During the Main Study Phase [ Time Frame: From Day 1 to Day 7 after vaccination 1, 2 or 3 at Month 0, 2 and 6 respectively ]
    Participants or their legal guardians were required to record any solicited local and systemic adverse events in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema (redness), swelling and induration (hardening). Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever. Two-sided 95% confidence intervals were calculated according to Altman method.
  • Geometric Mean Titers (GMTs) for Immunoglobulin G (IgG) Against Each Outer Surface Protein A (OspA) Serotype (ST1 to ST6) at Day 208 During the Main Study Phase [ Time Frame: Day 208 (Month 7) ]
    GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay at Day 208 is presented in this outcome measure.
Original Primary Outcome Measures  ICMJE
 (submitted: March 15, 2021)
  • Frequency of solicited local and solicited systemic AEs (Adverse Events) [ Time Frame: 7 Days ]
    Frequency of solicited local and solicited systemic AEs (Adverse Events) within 7 days after each and any vaccination of the primary vaccination series (Part A)
  • GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype [ Time Frame: Day 208/Month 7 ]
    GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype ST1 to ST6, determined by an IgG (Immunoglobulin G) binding assay at Day 208/Month 7 (Part A).
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 10, 2023)
  • Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Booster Dose [ Time Frame: Within 7 days after booster dose ]
    Participants or their legal guardians were required to record any solicited local and systemic adverse events in the electronic diary. Solicited local AEs included pain, tenderness, erythema (redness), swelling and induration (hardening). Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.
  • Percentage of Participants With Serious Adverse Events (SAEs) [ Time Frame: From Day 1 of vaccination up to Day 208 (Month 7) ]
    SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was another medically important condition. Two-sided 95% confidence intervals were calculated according to Altman method.
  • Percentage of Participants With Adverse Events of Special Interest (AESIs) [ Time Frame: From Day 1 of vaccination up to Day 208 (Month 7) ]
    An AESI (serious or non-serious) was one of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor were appropriate. Two-sided 95% confidence intervals were calculated according to Altman method.
  • Percentage of Participants With Unsolicited Adverse Events [ Time Frame: From Day 1 to Day 28 after vaccination 1, 2 and 3 at Month 0, 2 and 6, respectively ]
    An AE was any untoward medical occurrence in a participant administered an investigational product, whether or not related to this treatment. Unsolicited AEs were defined as any solicited local or systemic AE if it had an onset date more than 6 days after vaccination or any other symptom or untoward medical event. Two-sided 95% confidence intervals were calculated according to Altman method.
  • Percentage of Participants With SAEs, AESIs, Solicited and Unsolicited AEs Stratified by Age Group [ Time Frame: SAEs, AESIs: From Day 1 of vaccination (vac) up to Day 208 (Month 7), Solicited AEs: From Day 1 to Day 7 after vac 1, 2 and 3 at Month 0, 2 and 6, respectively; Unsolicited AEs: From Day 1 to Day 28 after vac 1, 2 and 3 at Month 0, 2 and 6, respectively ]
    Percentage of participants with SAEs, AESIs, solicited and unsolicited AEs stratified by age group 18 to 65, 12 to 17 and 5 to 11 years were reported. SAE: any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was another medically important condition. AESI: scientific and medical concern specific to the sponsor's product or program. Solicited AE: predefined reactions at injection site or systemic reactions after each vaccination. Unsolicited AEs: any solicited local or systemic AE if it had an onset date more than 6 days after vaccination or any other symptom or untoward medical event. Unsolicited AEs were collected only up to 28 days after any vaccination. Two-sided 95% confidence intervals were calculated according to Altman method.
  • GMTs for IgG Against Each OspA Serotype (ST1 to ST6) at Baseline, Day 85, Day 180 and Day 194 During the Main Study Phase [ Time Frame: Baseline, Day 85, Day 180 and Day 194 ]
    GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay.
  • Seroconversion Rate for Each OspA Serotype (ST1 to ST6) Specific IgG at Day 85, 180, 194 and 208 [ Time Frame: Day 85, Day 180, Day 194 and Day 208 ]
    Seroconversion Rate (SCR) for each OspA serotype specific IgG ST1 to ST6, determined by enzyme linked immunosorbent assay (ELISA). Seroconversion for ELISA was defined as: 1) For participants who were seronegative at screening: percentage of participants with a change from seronegative at screening to seropositive (i.e. antibody titer of >=40 Units per milliliter [U/mL]) at a certain time point. 2) For participants who were seropositive at screening: percentage of participants with a >= 4-fold rise in OspA IgG antibody titer from screening.
  • Geometric Mean of the Fold Rise (GMFR) for IgG Against Each OspA Serotype (ST1 to ST6) at Day 85 and Day 208 During the Main Study Phase [ Time Frame: Baseline, Day 85 and 208 ]
    GMFR as compared to baseline for IgG against each OspA serotype ST1 to ST6, determined by IgG binding assay at Day 85 and Day 208.
  • GMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group at Baseline, Day 85, Day 180, Day 194 and Day 208 During the Main Study Phase [ Time Frame: Baseline, Day 85, Day 180, Day 194 (18 to 65 years only) and Day 208 ]
    GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay stratified by age group (18 to 65, 12 to 17 and 5 to 11 years).
  • Seroconversion Rate for Each OspA Serotype (ST1 to ST6) Specific IgG at Day 85, 180, 194 and 208 Stratified by Age Group During the Main Study Phase [ Time Frame: Day 85, Day 180, Day 194 (18 to 65 years only) and Day 208 ]
    SCR for each OspA serotype specific IgG ST1 to ST6, determined by ELISA stratified by age group (18 to 65, 12 to 17 and 5 to 11 years). Seroconversion for ELISA was defined as: 1) For participants who were seronegative at screening: percentage of participants with a change from seronegative at screening to seropositive (i.e. antibody titer of >=40 Units per milliliter [U/mL]) at a certain time point. 2) For participants who were seropositive at screening: percentage of participants with a >= 4-fold rise in OspA IgG antibody titer from screening.
  • Geometric Mean of the Fold Rise (GMFR) for IgG Against Each OspA Serotype (ST1 to ST6) at Day 85, Day 180, Day 194 and Day 208 Stratified by Age Group During the Main Study Phase [ Time Frame: Baseline, Day 85, Day 180, Day 194 (18 to 65 years only) and Day 208 ]
    GMFR as compared to baseline for IgG against each OspA serotype ST1 to ST6, stratified by age group (18 to 65, 12 to 17 and 5 to 11 years) determined by IgG binding assay at Day 85, Day 180, Day 194 (18 to 65 years only) and Day 208.
  • GMTs for IgG Against Each OspA Serotype (ST1 to ST6) During the Booster Phase [ Time Frame: Up to Month 54 ]
  • SCR for Each OspA Serotype (ST1 to ST6) IgG During the Booster Phase [ Time Frame: Up to Month 54 ]
    Seroconversion for ELISA was defined as: 1) For participants who were seronegative at screening: a change from seronegative at screening to seropositive (i.e. antibody titer of >=40 U/mL) at a certain time point. 2) For participants who were seropositive at screening: a >= 4-fold rise in OspA IgG antibody titer from screening.
  • GMFR for IgG Against Each OspA Serotype (ST1 to ST6) at Month 19 During the Booster Phase [ Time Frame: Month 19 ]
  • GMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Cohort During the Booster Phase [ Time Frame: Up to Month 54 ]
  • SCR for Each OspA Serotype (ST1 to ST6) IgG Stratified by Age Cohort During the Booster Phase [ Time Frame: Up to Month 54 ]
    Seroconversion for ELISA was defined as: 1) For participants who were seronegative at screening: a change from seronegative at screening to seropositive (i.e. antibody titer of >=40 U/mL) at a certain time point. 2) For participants who were seropositive at screening: a >= 4-fold rise in OspA IgG antibody titer from screening.
  • GMFR for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Cohort During the Booster Phase [ Time Frame: Up to Month 54 ]
Original Secondary Outcome Measures  ICMJE
 (submitted: March 15, 2021)
  • Frequency of solicited local and solicited systemic AEs (Adverse Events) [ Time Frame: 7 Days ]
    Frequency of solicited local and solicited systemic AEs (Adverse Events) within 7 days after booster dose administration (Part B)
  • Frequency of SAEs (Serious Adverse Events) [ Time Frame: until Month 54 ]
    Frequency of SAEs (Serious Adverse Events) during the entire study
  • Frequency of AESIs (Adverse Events of Special Interest) [ Time Frame: until Month 54 ]
    Frequency of AESIs (Adverse Events of Special Interest) during the entire study.
  • Frequency of unsolicited AEs (Adverse Events) after each vaccination [ Time Frame: 28 Days ]
    Frequency of unsolicited AEs (Adverse Events) within 28 days after each vaccination
  • Frequency of SAEs (Serious Adverse Events), AESIs(Adverse Events of Special Interest), unsolicited and solicited AEs stratified by age cohort [ Time Frame: until Month 54 ]
    Frequency of SAEs (Serious Adverse Events), AESIs (Adverse Events of Special Interest), unsolicited and solicited AEs (Adverse Events) stratified by age cohort
  • GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (Part A) [ Time Frame: until Month 18 ]
    GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (ST1 to ST6), determined by an IgG (Immunoglobulin G) binding assay, at baseline (screening visit) and at Day 85, 180, 194, 365 and Month 18 (Part A)
  • SCRs (Seroconversion Rates) for each OspA (Outer Surface Protein A) serotype specific IgG (Immunoglobulin G) (Part A) [ Time Frame: until Month 18 ]
    SCRs (Seroconversion Rates) for each OspA (Outer Surface Protein A) serotype specific IgG (Immunoglobulin G) (ST1 to ST6), determined by an IgG (Immunoglobulin G) binding assay, at Day 85, 180, 194, 208, 365 and Month 18 (Part A)
  • GMFRs (Geometric Mean of the Fold Rises) for IgG against each OspA (Outer Surface Protein A) serotype (Part A) [ Time Frame: until Day 208 ]
    GMFRs (Geometric Mean of the Fold Rises) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (ST1 to ST6), determined by an IgG (Immunoglobulin G) binding assay, at Day 85 and 208 (Part A)
  • GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype stratified by age cohort (Part A) [ Time Frame: until Month 19 ]
    GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (ST1 to ST6), determined by an IgG (Immunoglobulin G) binging assay, at specified time-points, stratified by age cohort. (Part A)
  • SCRs (Seroconversion Rates) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype stratified by age cohort (Part A) [ Time Frame: until Month 19 ]
    SCRs (Seroconversion Rates) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (ST1 to ST6), determined by an IgG (Immunoglobulin G) binging assay, at specified time-points, stratified by age cohort. (Part A)
  • GMFRs (Geometric Mean Fold Rises) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype stratified by age cohort (Part A) [ Time Frame: until Month 19 ]
    GMFRs (Geometric Mean Fold Rises) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (ST1 to ST6), determined by an IgG (Immunoglobulin G) binging assay, at specified time-points, stratified by age cohort. (Part A)
  • GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (Part B) [ Time Frame: until Month 54 ]
    GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (ST1 to ST6), determined by an IgG (Immunoglobulin G) binding assay, at Month 18, 19, 23, 26, 30, 36, 42, 48 and 54 (Part B)
  • SCRs (Seroconversion Rates) for each OspA (Outer Surface Protein A) serotype specific IgG (Immunoglobulin G) (Part B) [ Time Frame: until Month 54 ]
    SCRs (Seroconversion Rates) for each OspA (Outer Surface Protein A) serotype specific IgG (ST1 to ST6), determined by an IgG (Immunoglobulin G) binding assay, at Month 18, 19, 23, 26, 30, 36, 42, 48 and 54 (Part B)
  • GMFRs (Geometric Mean of the Fold Rises) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (Part B) [ Time Frame: Month 19 ]
    GMFRs (Geometric Mean of the Fold Rises) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (ST1 to ST6), determined by an IgG (Immunoglobulin G) binding assay, at Month 19 (Part B)
  • GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype stratified by age cohort (Part B) [ Time Frame: until Month 54 ]
    GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (ST1 to ST6), determined by an IgG (Immunoglobulin G) binding assay, at specified time-points, stratified by age cohort. (Part B)
  • SCRs (Seroconversion Rates) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype stratified by age cohort (Part B) [ Time Frame: until Month 54 ]
    SCRs (Seroconversion Rates) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (ST1 to ST6), determined by an IgG (Immunoglobulin G) binding assay, at specified time-points, stratified by age cohort. (Part B)
  • GMFRs (Geometric Mean Fold Rises) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype stratified by age cohort (Part B) [ Time Frame: until Month 54 ]
    GMFRs (Geometric Mean Fold Rises) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (ST1 to ST6), determined by an IgG (Immunoglobulin G) binding assay, at specified time-points, stratified by age cohort. (Part B)
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population
Official Title  ICMJE SAFETY AND IMMUNOGENICITY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS: A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY IN A HEALTHY PEDIATRIC AND ADULT STUDY POPULATION
Brief Summary VLA15-221 is a Phase 2 study, which will be conducted in two parts: Main Study Phase (Part A) and Booster Phase (Part B). The study will compare the safety and immunogenicity of two different primary immunization schedules applying three (Month 0-2-6) or two (Month 0- 6) vaccinations. Within the study, 600 healthy subjects aged 5-65 years will be included. Subjects with a history of Lyme borreliosis (previous infection with Borrelia) as well as Borrelia naïve subjects will be enrolled. Study duration per subject will be a maximum of 56 months per subject.
Detailed Description VLA15-221 is a randomized, observer-blind, placebo controlled, multicenter Phase 2 study, which is set up in two parts: Main Study Phase (Part A) and Booster Phase (Part B). In Part A 600 subjects aged 5-65 years will be enrolled 1:1:1 into three groups: Group 1 will be vaccinated with VLA15 at Month 0-2-6, Group 2 will be vaccinated with VLA15 at Month 0-6 and with placebo at Month 2 and Group 3 will be vaccinated with placebo at Month 0-2-6. In Part B all eligible subjects will receive a booster injection with VLA15 or placebo at Month 18 and 30.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Condition  ICMJE Lyme Borreliosis
Intervention  ICMJE
  • Biological: VLA15
    a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
  • Biological: Placebo
    PBS (Phosphate Buffered Saline)
Study Arms  ICMJE
  • Experimental: Part A+B - Group 1
    Part A: VLA15 at Month 0, 2 and 6 Part B: VLA15 at Month 18 and 30
    Intervention: Biological: VLA15
  • Experimental: Part A+B - Group 2
    Part A: VLA15 at Month 0 and 6, placebo at Month 2 Part B: VLA15 at Month 18 and 30
    Interventions:
    • Biological: VLA15
    • Biological: Placebo
  • Placebo Comparator: Part A+B - Group 3
    Part A: Placebo at Month 0, 2 and 6 Part B: Placebo at Month 18 and 30
    Intervention: Biological: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: July 26, 2021)		 625
Original Estimated Enrollment  ICMJE
 (submitted: March 15, 2021)		 600
Estimated Study Completion Date  ICMJE January 22, 2026
Actual Primary Completion Date March 25, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subject is aged 5 to 65 years at the day of screening (Visit 0)
  • Subject is of good general health

  • Parent(s)/legal representative(s) and subject understand the study and its procedures, agree to its provisions

    • for subjects aged 18-65 years: written informed consent prior to any study related procedures
    • for subjects aged 5-17 years: written informed consent by the subject's legal representative(s), according to local requirements, and written informed assent of the subject, if applicable, prior to any study related procedures.

  • If subject is of childbearing potential: Subject has a negative serum pregnancy test at screening (Visit 0) and agrees to employ adequate birth control measures according to following timelines:

    • Main Study Phase: duration of entire study
    • Booster Phase: until 5 months after first booster (i.e Month 23) and second booster (i.e. Month 35)
  • Subject is willing and able to comply with scheduled visits, treatment plan, and other study procedures
  • Subject is available for the duration of the study and can be contacted by telephone during study participation

Exclusion Criteria:

  • Subject has a chronic illness related to Lyme borreliosis (LB), an active symptomatic LB, or received treatment for LB within the last 3 months prior to Day 1;
  • Subject received previous vaccination against LB;
  • Subject had a tick bite within 4 weeks prior to Day 1;
  • Subject has a medical history of or currently has a clinically relevant disease;
  • Subject has a medical history of or currently has a neuro- inflammatory or autoimmune disease;
  • Subject has a known thrombocytopenia, bleeding disorder, or received anticoagulants in the 3 weeks prior to Day 1;
  • Subject has received an active or passive immunization within 4 weeks prior to Day 1;
  • Subject has received any other registered or non-registered medicinal product in another clinical trial within 4 weeks prior to vaccination at Day 1;
  • Subject has a known or suspected defect of the immune system or received immuno-suppressive therapy within 4 weeks prior to Day 1;
  • Subject has a history of anaphylaxis of unknown cause or severe allergic reactions of unknown cause or has a known hypersensitivity or allergic reactions to one of the components of the vaccine;
  • Subject had any malignancy in the past 5 years;
  • Subject is pregnant, has plans to become pregnant during the course of the study or is lactating at the time of enrollment;
  • Subject has donated or plans to donate blood or blood-derived products 4 weeks prior to Day 1;
  • Subject has any condition that may compromise its well-being, might interfere with evaluation of study endpoints, or would limit the subject's ability to complete the study;
  • Subject is in a dependent relationship
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 5 Years to 65 Years   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries Germany
 
Administrative Information
NCT Number  ICMJE NCT04801420
Other Study ID Numbers  ICMJE VLA15-221
C4601008 ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
URL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests
Current Responsible Party Pfizer
Original Responsible Party Valneva Austria GmbH
Current Study Sponsor  ICMJE Pfizer
Original Study Sponsor  ICMJE Valneva Austria GmbH
Collaborators  ICMJE Valneva Austria GmbH
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
Principal Investigator: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date March 2024

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP